Sarepta Gene Therapy Suspension - Search News

Order byBest matchMost fresh

News

Gene Therapy, Sarepta

Following Sarepta’s Lead, Roche Suspends Elevidys Shipments to Some Ex-US Countries

Discovered and developed by Sarepta Therapeutics, Elevidys is a gene therapy that won accelerated approval in June 2023 and full approval in June 2024. Roche partnered with Sarepta in December 2019, paying $1.15 billion upfront in cash and stock for the right to launch and market Elevidys outside the U.S.

Continue reading

Devdiscourse · 4d

Sarepta Suspends Gene Therapy Shipments After Tragic Deaths

Sarepta Shares Fall After Gene Therapy Hits Another Regulatory Roadblock

13hon MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

Precision Medicine Online1d

Sarepta Halts Duchenne Gene Therapy Sales Amid FDA Scrutiny, Raising Concerns Over Financial Future

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results